SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/3B172BBC2A0CDFB6BC2C16D140AB20A082DC2380DEDBBDAFAF182D5AFD332ED414BA2EFB0189BC2FF07EDDE878EBC8B1>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/3B172BBC2A0CDFB6BC2C16D140AB20A082DC2380DEDBBDAFAF182D5AFD332ED414BA2EFB0189BC2FF07EDDE878EBC8B1
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/3B172BBC2A0CDFB6BC2C16D140AB20A082DC2380DEDBBDAFAF182D5AFD332ED414BA2EFB0189BC2FF07EDDE878EBC8B1
http://www.w3.org/2000/01/rdf-schema#comment
"Results suggest that sequential ALK inhibitors can foster the emergence of compound ALK mutations conferring high level resistance to lorlatinib in ALK-positive lung neoplasm."
xsd:string
http://purl.uniprot.org/uniprot/#_AA375BB4AF01E8BF9C0CC3A84E177541C07794252BE3336660DE841D318E94226D24330C54BCE3DCDF03162E181A8C8A
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/3B172BBC2A0CDFB6BC2C16D140AB20A082DC2380DEDBBDAFAF182D5AFD332ED414BA2EFB0189BC2FF07EDDE878EBC8B1
http://purl.uniprot.org/uniprot/B6D4Y2
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/3B172BBC2A0CDFB6BC2C16D140AB20A082DC2380DEDBBDAFAF182D5AFD332ED414BA2EFB0189BC2FF07EDDE878EBC8B1
http://purl.uniprot.org/uniprot/#_B6D4Y2-mappedCitation-29650534
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/3B172BBC2A0CDFB6BC2C16D140AB20A082DC2380DEDBBDAFAF182D5AFD332ED414BA2EFB0189BC2FF07EDDE878EBC8B1